Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
DIFFUSE MALIGNANT PLEURAL MESOTHELIOMA IN DIAGNOSIS, THERAPY, AND PROGNOSIS - A REVIEW
Autore:
MANEGOLD C; LATZ D; SCHIRREN J; SCHNEIDER P; SCHRAUBE P; DRINGS P; VOGTMOYKOPF I; WANNENMACHER M;
Indirizzi:
LVA BADEN,ABT INNERE MED ONKOL & CHIRURG,THORAXKLIN HEIDELBERG,AMALIENSTR 5 D-69126 HEIDELBERG GERMANY LVA BADEN,ABT INNERE MED ONKOL & CHIRURG,THORAXKLIN HEIDELBERG D-69126 HEIDELBERG GERMANY UNIV HEIDELBERG,KLIN RADIOTHERAPIE HEIDELBERG GERMANY
Titolo Testata:
Onkologie
fascicolo: 1, volume: 20, anno: 1997,
pagine: 64 - 69
SICI:
0378-584X(1997)20:1<64:DMPMID>2.0.ZU;2-6
Fonte:
ISI
Lingua:
GER
Soggetto:
188 CONSECUTIVE PATIENTS; PHASE-II; EXTRAPLEURAL PNEUMONECTOMY; MULTIMODALITY THERAPY; CANCER-INSTITUTE; CHEMOTHERAPY; CISPLATIN; TRIAL; ADENOCARCINOMA; THORACOSCOPY;
Keywords:
PLEURAL MESOTHELIOMA; DIAGNOSIS; THERAPY; PROGNOSIS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
69
Recensione:
Indirizzi per estratti:
Citazione:
C. Manegold et al., "DIFFUSE MALIGNANT PLEURAL MESOTHELIOMA IN DIAGNOSIS, THERAPY, AND PROGNOSIS - A REVIEW", Onkologie, 20(1), 1997, pp. 64-69

Abstract

The incidence of diffuse, malignant pleural mesothelioma is closely related to occupational asbestos exposure. Furthermore, this disease isthe most frequently found occupational cancer. Due to the long latency period between exposure and tumor manifestation, diffuse malignant pleural mesothelioma is most commonly found in patients with 50 to 70 years of age. Currently due to the fact that no standard therapy exists, pragmatic individual treatment decisions are the rule and include surgery, radiotherapy, chemotherapy or simply a symptomatic relief Survival chances are best when the tumor can be completely removed by surgery. Surgical options to be considered are the extrapleural pneumonectomy, pleurectomy or decortication, the partial pleurectomy and thoracosocopy with subsequent pleural drainage and durg instillation. Radiotherapy is employed palliatively to relieve symptoms and prevent complications. Unfortunately, the diffuse, malignant peural mesothelioma has proved to be exceptionally resistant to chemotherapy. No standard cytotoxic treatment has been developed. The most frequently used chemotherapy has included anthracycline and cisplatin, where the response rates range from 10 to 20%. Complete remissions are never achieved. Combination chemotherapy has not proven to have any advantage over single agent therapy. There is also no evidence that the use of chemotherapy within multimodality treatment protocols, including radiotherapy and/or surgery, can improve results. New cytotoxic drugs, such as taxans or gemcitabine, are currently being clinically tested. The comparatively high response rates shown by high-dose methotrexate and edatraxate have yet to be confirmed. The purpose of this report is to summarize the current status of diffuse malignant pleural mesothelioma - its diagnosis,therapy, and prognosis.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/12/20 alle ore 16:40:17